• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

3D Printed Drugs Market to Reach US$ 2,064.8 Million by 2027 Globally | CAGR: 15.2%

Share:

February 10, 2021

A comprehensive overview of the 3D printed drugs market is recently added by UnivDatos Market Insights to its humongous database. The 3D Printed Drugs market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the 3D printed drugs market. The 3D printed drugs market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the 3D Printed Drugs market at the global and regional levels. The Global 3D Printed Drugs market is expected to grow at a CAGR of 15.2% from 2021-2027 to reach US$ 2,064.8 million by 2027.

Market Overview

The proliferating prevalence of chronic disease coupled with the surging number of patients with dysphagia across the globe is leading to the growing demand for instantaneous soluble drugs therefore the market of 3D printed is witnessing an uptick. In a report, it was found that the prevalence of dysphagia in the general population of 29 years to 32 years is around 16-23% which is increasing to 27% in those over 76 years of age. Also, a surge in the geriatric population is demanding soluble and personalized drugs. Many older people will have swallowing problems. The prevalence of dysphagia increases with the degree of frailty present and the degree of dependence irrespective of ethnicity. As per the United Nations, there were 703 million persons aged 65 years or over in the world in 2019 and the number of older persons is projected to double to 1.5 billion in 2050. Also, as per the Brazilian Journal of Otorhinolaryngology, approximately 36% of the total population and 65 million people were got affected by dysphagia in 2017 and the count is increasing at a steady growth. Furthermore, technological advancements in healthcare owing to the rapidly increasing demand for medicines coupled with the government’s emphasis and investments in the 3D printing industry is also contributing to the growth of the market.

Read more here

Source: Prnews Wire

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Blockchain to ensure safety of clinical trial dataBlockchain to ensure safety of clinical trial data
  • Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic PracticesRevance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices
  • iGambit and Clinigence Holdings Announce Transformational MergeriGambit and Clinigence Holdings Announce Transformational Merger
  • Fulgent Genetics Announces Acquisition of CSI LaboratoriesFulgent Genetics Announces Acquisition of CSI Laboratories
  • EGenesis Expands Research Collaboration with Leading Academic Medical CenterEGenesis Expands Research Collaboration with Leading Academic Medical Center
  • Enochian Biosciences Expands Its Infectious Disease Pipeline By Entering Into An Agreement in Principle to Acquire An Exclusive License for a Novel Hepatitis B Virus TreatmentEnochian Biosciences Expands Its Infectious Disease Pipeline By Entering Into An Agreement in Principle to Acquire An Exclusive License for a Novel Hepatitis B Virus Treatment
  • Insuretech Firm Qumata’s Extended Series a Round Hits $23MInsuretech Firm Qumata’s Extended Series a Round Hits $23M
  • List of top Medical Device Companies with Early Stage Venture FundingList of top Medical Device Companies with Early Stage Venture Funding

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications